A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Journal:

Nature Medicine

Published:

2025-06-03

DOI:

10.1038/s41591-025-03743-2

Affiliations:

19

Authors:

27

Go to article

Institutions	Authors	Share
Insilico Medicine, China	6.500000	0.24
Insilico Medicine, United States of America (USA)	3.250000	0.12
Peking Union Medical College Hospital (PUMCH), China	2.000000	0.07
Insilico Medicine Abu Dhabi, United Arab Emirates	1.250000	0.05
The General Hospital, TMU, China	1.000000	0.04
Beijing Friendship Hospital, Capital Medical University, China	1.000000	0.04
Qilu Hospital of Shandong University, China	1.000000	0.04
Shengjing Hospital of China Medical University, China	1.000000	0.04
Drum Tower Hospital, China	1.000000	0.04
Hainan General Hospital, China	1.000000	0.04
Anhui Chest Hospital, China	1.000000	0.04
Shanghai Pulmonary Hospital, China	1.000000	0.04
First Affiliated Hospital, ZZU, China	1.000000	0.04
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.04
Nanfang Hospital, China	1.000000	0.04
Xiangya Hospital, CSU, China	1.000000	0.04
Peking University Shougang Hospital, China	1.000000	0.04
Jiangxi Provincial People's Hospital, China	1.000000	0.04

Interested in Cardiovascular Medicine and Haematology?